May 14 |
Candel Therapeutics GAAP EPS of -$0.28
|
May 14 |
Candel Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Recent Corporate Highlights
|
Apr 25 |
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
|
Apr 19 |
How Is The Market Feeling About Candel Therapeutics?
|
Apr 15 |
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
|
Apr 12 |
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
|
Apr 11 |
Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment
|
Apr 11 |
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
|
Apr 9 |
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
|
Apr 6 |
Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
|